Find out how strategic acquisitions are reshaping the pharma landscape in our latest analysis of Q3 2025 M&A activity. Despite a drop in the number of deals, total deal values have soared—up 210% compared to last year—signaling renewed confidence and bold investment in de-risked, high-value assets.

Learn how soaring deal values and evolving risk strategies can inform smarter decisions:

• Spot Market Shifts: Learn why deal values are climbing even as volumes remain modest, and what this means for your commercial strategy.
• Identify Growth Opportunities: See which therapeutic areas—oncology, cardiometabolic, and respiratory—are driving the biggest deals, and where future investments are heading.
• Mitigate Risk: Understand how milestone payments and contingent value rights (CVRs) are being used to manage uncertainty and maximise portfolio value.
• Benchmark Against Industry Leaders: Explore the biggest transactions of the quarter—multi-billion-dollar acquisitions that signal bold moves in high-value therapeutic areas. See how leading players are leveraging strategic deals to strengthen portfolios and secure long-term growth.

Download the full article now to access exclusive intelligence from IQVIA’s Pharma Deals platform. Empower your team with actionable insights and stay ahead in the fast-evolving pharma M&A landscape.